News

DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

April 26, 2016

The Montreal Heart Institute Leads Worldwide Study. The Dalcetrapib to be Studied in Genetically Distinct Patients with Acute Coronary Syndrome (ACS). Global Study to be Conducted at 1,000 Sites in 33 Countries.

Read more

A World First - PulmoBind: A Biomarker for Diagnosing Pulmonary Hypertension

April 5, 2016

During the annual meeting of the American College of Cardiology (ACC) in Chicago, a researcher from the Montreal Heart Institute presented the results of a phase II clinical study demonstrating the safety of the PulmoBind biomarker and the ability of the PulmoBind tomography (SPECT) scan to clearly show abnormal results in patients with pulmonary hypertension.

Read more

Blogue